JP2019523221A5 - - Google Patents

Download PDF

Info

Publication number
JP2019523221A5
JP2019523221A5 JP2018561225A JP2018561225A JP2019523221A5 JP 2019523221 A5 JP2019523221 A5 JP 2019523221A5 JP 2018561225 A JP2018561225 A JP 2018561225A JP 2018561225 A JP2018561225 A JP 2018561225A JP 2019523221 A5 JP2019523221 A5 JP 2019523221A5
Authority
JP
Japan
Prior art keywords
sequence
antibody
seq
antibody according
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018561225A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019523221A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/034681 external-priority patent/WO2017205742A1/en
Publication of JP2019523221A publication Critical patent/JP2019523221A/ja
Publication of JP2019523221A5 publication Critical patent/JP2019523221A5/ja
Priority to JP2022023569A priority Critical patent/JP7331179B2/ja
Withdrawn legal-status Critical Current

Links

JP2018561225A 2016-05-27 2017-05-26 抗ｃｄ４０抗体とその使用 Withdrawn JP2019523221A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022023569A JP7331179B2 (ja) 2016-05-27 2022-02-18 抗ｃｄ４０抗体とその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662342417P 2016-05-27 2016-05-27
US62/342,417 2016-05-27
PCT/US2017/034681 WO2017205742A1 (en) 2016-05-27 2017-05-26 Anti-cd40 antibodies and their uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022023569A Division JP7331179B2 (ja) 2016-05-27 2022-02-18 抗ｃｄ４０抗体とその使用

Publications (2)

Publication Number Publication Date
JP2019523221A JP2019523221A (ja) 2019-08-22
JP2019523221A5 true JP2019523221A5 (enExample) 2020-07-02

Family

ID=59014833

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018561225A Withdrawn JP2019523221A (ja) 2016-05-27 2017-05-26 抗ｃｄ４０抗体とその使用
JP2022023569A Active JP7331179B2 (ja) 2016-05-27 2022-02-18 抗ｃｄ４０抗体とその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022023569A Active JP7331179B2 (ja) 2016-05-27 2022-02-18 抗ｃｄ４０抗体とその使用

Country Status (35)

Country Link
US (8) US10519243B2 (enExample)
EP (2) EP3995511A1 (enExample)
JP (2) JP2019523221A (enExample)
KR (2) KR102366355B1 (enExample)
CN (1) CN109476750B (enExample)
AR (2) AR108611A1 (enExample)
AU (1) AU2017271602A1 (enExample)
BR (1) BR112018074468A2 (enExample)
CA (1) CA3025347A1 (enExample)
CL (1) CL2018003366A1 (enExample)
CO (1) CO2018012699A2 (enExample)
CR (1) CR20180605A (enExample)
CY (1) CY1124806T1 (enExample)
DO (1) DOP2018000258A (enExample)
EC (1) ECSP18094829A (enExample)
ES (1) ES2901722T3 (enExample)
HR (1) HRP20211882T1 (enExample)
HU (1) HUE056670T2 (enExample)
IL (1) IL263223B2 (enExample)
LT (1) LT3464361T (enExample)
MX (1) MX393455B (enExample)
MY (1) MY195442A (enExample)
NZ (1) NZ748644A (enExample)
PE (1) PE20190970A1 (enExample)
PH (1) PH12018502456A1 (enExample)
PL (1) PL3464361T3 (enExample)
PT (1) PT3464361T (enExample)
RS (1) RS62726B1 (enExample)
RU (1) RU2752049C2 (enExample)
SG (2) SG10201914132RA (enExample)
SI (1) SI3464361T1 (enExample)
SM (1) SMT202100721T1 (enExample)
TW (2) TWI814279B (enExample)
UA (1) UA123111C2 (enExample)
WO (1) WO2017205742A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101969990B (zh) * 2007-11-01 2014-07-09 阿肯色大学评议会 增强针对艾美球虫属的免疫反应的组合物和方法
SG10201914132RA (en) * 2016-05-27 2020-03-30 Abbvie Biotherapeutics Inc Anti-cd40 antibodies and their uses
AU2019255781A1 (en) * 2018-04-20 2020-10-29 Lyvgen Biopharma Holdings Limited Anti-CD40 antibodies and uses thereof
WO2020104690A1 (en) 2018-11-23 2020-05-28 Quine Medical Ab Bi-specific conjugates
JP2022509156A (ja) * 2018-11-30 2022-01-20 江蘇恒瑞医薬股▲ふん▼有限公司 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用
CN111548415B (zh) * 2019-03-04 2021-04-20 北京天广实生物技术股份有限公司 与cd40特异结合的抗体及其用途
US10570210B1 (en) * 2019-03-04 2020-02-25 Beijing Mabworks Biotech Co.Ltd Antibodies binding CD40 and uses thereof
WO2020193718A1 (en) 2019-03-27 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Recombinant proteins with cd40 activating properties
CA3136491A1 (en) * 2019-04-10 2020-10-15 Nankai University Anti-cd40 antibodies and uses thereof
GB201910900D0 (en) * 2019-07-31 2019-09-11 Scancell Ltd Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
US20220370418A1 (en) 2019-09-09 2022-11-24 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
KR20220062036A (ko) * 2019-09-11 2022-05-13 노파르티스 아게 환자에서 인간 바이러스 연관된 장애를 방지하는 방법
CA3158527A1 (en) * 2019-10-23 2021-04-29 Lyvgen Biopharma Holdings Limited Anti-cd40 binding molecules and bi-specific antibodies comprising such
US20230002492A1 (en) * 2019-11-08 2023-01-05 Simcere (Shanghai) Pharmaceutical Co., Ltd. Anti-human programmed cell death ligand-1 (pd-l1) antibody and use thereof
AU2020398327A1 (en) 2019-12-03 2022-07-14 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
GB202008003D0 (en) 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
EP4185320A4 (en) * 2020-07-23 2025-10-08 Dyne Therapeutics Inc MUSCLE TARGETING COMPLEXES AND THEIR USES IN THE TREATMENT OF MUSCLE ATROPHY
CN115403670A (zh) * 2021-05-26 2022-11-29 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途
KR20250019077A (ko) * 2022-05-31 2025-02-07 퓨쳐진 바이오파머쓰티컬 (베이징) 코., 엘티디. 항-cd40 항체 및 항-pd-l1×cd40 이중특이성 항체 및 이의 용도
JP2025530110A (ja) * 2022-09-20 2025-09-11 カーラス・バイオロジクス・ピーティーワイ・リミテッド 二重特異性ポリペプチド及びその使用
TW202500587A (zh) * 2023-02-16 2025-01-01 法商賽諾菲公司 Cd40結合蛋白

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
JP2002530081A (ja) 1998-11-18 2002-09-17 ジェネンテック・インコーポレーテッド 親抗体より高度な結合親和性を持つ抗体変異体
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
BR0108001A (pt) 2000-02-01 2004-01-06 Tanox Inc Moléculas ativadoras de apc com ligação para cd-40
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
RU2377254C2 (ru) * 2003-12-25 2009-12-27 Кирин Фарма Кабусики Кайся Мутанты анти-cd40 антитела
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006017173A1 (en) * 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US20090074711A1 (en) 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
CN103694349A (zh) * 2006-09-08 2014-04-02 米迪缪尼有限公司 人源化抗cd19抗体及其在治疗癌症、移植病和自身免疫病中的应用
AU2008311365B2 (en) * 2007-10-05 2015-03-12 Ac Immune S.A. Humanized antibody
RS60612B1 (sr) * 2010-03-31 2020-08-31 Boehringer Ingelheim Int Anti-cd40 antitela
CN103635488B (zh) 2011-04-29 2016-12-14 埃派斯进有限公司 抗-cd40抗体及其使用方法
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
TWI855488B (zh) * 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
EP2914627B1 (en) * 2012-10-30 2021-04-07 Apexigen, Inc. Anti-cd40 antibodies and methods of use
MX368665B (es) * 2013-03-15 2019-10-10 Abbvie Biotherapeutics Inc Variantes de fc.
GB201322583D0 (en) * 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
AU2015339128C1 (en) 2014-10-29 2021-12-16 Seagen Inc. Dosage and administration of non-fucosylated anti-CD40 antibodies
UY36692A (es) * 2015-05-29 2016-12-30 Abbvie Inc Anticuerpos anti-cd40 y usos de los mismos
SG10201914132RA (en) * 2016-05-27 2020-03-30 Abbvie Biotherapeutics Inc Anti-cd40 antibodies and their uses
CA3025345A1 (en) * 2016-05-27 2017-11-30 Abbvie Biotherapeutics Inc. Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen

Similar Documents

Publication Publication Date Title
JP2019523221A5 (enExample)
JP2020504101A5 (enExample)
RU2018146533A (ru) Антитела к cd40 и пути их применения
JP2019533989A5 (ja) 抗ｐｄ−１抗体及びその使用
JP2012254092A5 (enExample)
JP2017114866A5 (enExample)
JP2018121657A5 (enExample)
JP2018536393A5 (enExample)
RU2017115315A (ru) Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
JP2016511750A5 (enExample)
JP2015535828A5 (enExample)
JP2019527047A5 (enExample)
JP2018504105A5 (enExample)
ME03819B (me) Antitela za icos
RU2019110835A (ru) Антитела к pd-1(cd279)
JP2015146822A5 (enExample)
JP2018521638A5 (enExample)
JP2017522888A5 (enExample)
JP2017029157A5 (enExample)
JP2021501744A5 (enExample)
JP2012143232A5 (enExample)
JP2016185981A5 (enExample)
FI3390451T3 (fi) Kaninisoidut ihmisen vasta-aineet ihmisen ja koiraeläimen il-4r alfaa kohtaan
JP2012526542A5 (enExample)
JP2021500916A5 (enExample)